Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$53 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $721 |
| Gross Profit | $0 | $0 | $0 | $668 |
| % Margin | – | – | – | -1,260.4% |
| R&D Expenses | $6,528 | $5,118 | $4,074 | $6,598 |
| G&A Expenses | $3,649 | $4,132 | $3,797 | $5,201 |
| SG&A Expenses | $3,649 | $4,132 | $3,797 | $5,201 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,177 | $9,250 | $7,871 | $11,799 |
| Operating Income | $0 | $0 | $0 | $12,615 |
| % Margin | – | – | – | -23,801.9% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$11,345 | -$9,471 | -$8,185 | -$6,065 |
| Tax Expense | $0 | $0 | $0 | $73 |
| Net Income | -$11,345 | -$9,471 | -$8,185 | -$6,065 |
| % Margin | – | – | – | 11,443.4% |
| EPS | -1.03 | -0.86 | -74.32 | 1.07 |
| % Growth | -19.8% | 98.8% | -7,045.8% | – |
| EPS Diluted | -1.03 | -0.86 | -74.32 | 1.07 |
| Weighted Avg Shares Out | 11,064 | 11,053 | 110 | 2,226 |
| Weighted Avg Shares Out Dil | 11,064 | 11,053 | 110 | 2,226 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$610 |
| Interest Expense | $1,510 | $1,354 | $1,215 | -$3,887 |
| Depreciation & Amortization | $0 | $0 | $0 | $30 |
| EBITDA | -$9,835 | $0 | $0 | $12,645 |
| % Margin | – | – | – | -23,858.5% |